Kornimate/medical-research-clean huggingface dataset:
tranexamic acid and head and neck surgery patients

Conditions: Head and Neck Neoplasms

Summary: tranexamic acid belongs to fibrinolytic inhibitors. several prospective randomized clinical trials have proved its effectiveness in reducing intra-operative and post-operative bleeding in orthopedic and cardiovascular surgeries. however, there is little study about tranexamic acid in reducing post-operative bleeding in head and neck surgery. so the aim of this study is to investigate if tranexamic acid could reduce post-operative bleeding via prospective double-blinded randomized clinic trial.

otolaryngologists often use drainage tube after head and neck surgery to reduce hematoma or seroma formation. in addition, the duration of drainage tube placement is closely related to the length of hospital stay. so early removal of drainage tube could eventually shorten the admission period. the factors related to the duration of drainage tube placement include: type of surgery, intra-operative bleeding, underlying disease of coagulation disorders, etc. according to the literatures, the average duration of drainage in head and neck surgery is 4 days. another study showed that one of the risk factors associated with surgical site infection is the longer drainage duration. therefore, how to remove drainage tube as soon as possible is crucial to head and neck surgeon.tranexamic acid belongs to fibrinolytic inhibitors. several prospective randomized clinical trials have proved its effectiveness in reducing intra-operative and post-operative bleeding in orthopedic and cardiovascular surgeries. however, there is little study about tranexamic acid in reducing post-operative bleeding in head and neck surgery. so the aim of this study is to investigate if tranexamic acid could reduce post-operative bleeding via prospective double-blinded randomized clinic trial.this study includes 60 consecutive patients who will undergo head and neck surgery. those who are allergy to tranexamic acid, history of coagulation disorders, under anti-coagulation therapy will be excluded. basic data will be recorded along with detail physical examination and operation type. then they will be divided randomly into study group and control group. study group will receive tranexamic acid before and after operation while control group not. pt, aptt, level of prothrombin fragments 1+2, d-dimers, plasminogen, α2-antiplasmin, tissue plasminogen activator (tpa), and plasminogen activator inhibitor (pai-1) will be obtained before and after operation. the drainage amount, duration of drainage tube placement will also be recorded. relevant variables will be collected and analyzed.

Eligibility criteria:
inclusion criteria: * head and neck neoplasm scheduled for operation exclusion criteria: * allergy to tranexamic acid * history of coagulation disorders * under anti-coagulation therapy

Keywords: tranexamic acid head neck surgery
amr of streptococcus pneumoniae carriage strains

Conditions: Infection

Summary: this study looks at the usage of human antibiotics for treatment of animals in bangladesh.


Eligibility criteria:
inclusion criteria: * bangladesh location exclusion criteria: * none

Keywords: animal antibiotics human antibiotics
pathological comparisons of surgical open lung biopsies and cryobiopsies in non-ipf ild

Conditions: Non Definite IPF; Interstitial Lung Diseases

Summary: pathological comparisons of surgical open lung biopsies and cryobiopsies in non-ipf ild. patients with non-ipf ild eligible for an open lung biopsy will undergo cryobiopsy in the same time. between observers agreement will be assessed for each pairs of samples.


Eligibility criteria:
inclusion criteria: * non ipf ild eligible for surgical lung biopsy reviewed during multidisciplinary approach exclusion criteria: * ineligible for lung biopsy: pulmonary hypertension, coagulation deficiency, fev\<11, giant emphysematous bullae, hemodynamic instability severe hypoxia, general anesthetic ineligibility

Keywords: ild pathology diagnosis lung biopsy
risk stratification of covid-19 using urine biomarkers

Conditions: Covid19; Urine; Biomarker; Acute Respiratory Failure With Hypoxia

Summary: coronavirus disease 2019 (covid-19) is caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) and in infected patients, it produces symptoms which range from completely asymptomatic to those expressing severe illness. early recognition of those developing severe manifestations allows for rapid and appropriate intervention, including admission to intensive care unit and intensive care therapy, such as mechanical ventilation. a current problem is that only limited data exist predicting the clinical course of covid-19. this study will determine whether non-invasive urinalysis is useful in assessing and predicting the severity or clinical course of patients with covid-19.

this study will conduct to elucidate the following clinical question; 1. if the single urinary biomarker or the combination of urinary biomarkers will clarify the risk of covid-19 confirmed mild cases. these biomarkers must be warranted to clinical use based on the evaluation by either ce or pmda or fda. examination should be done within 72 h after the start of covid-19. 2. if above addressed biomarker can classify the effectiveness of therapy directed to covid-19.

Eligibility criteria:
inclusion criteria: * covid-19 confirmed cases by qpcr exam or equivalent. * those who agreed to join this study * those who received treatment at ncgm, affiliated hospital and institute including accommodation facilities for observational purposes. exclusion criteria: * age less than 20 * those who do not have smart phone (no personal contract) * egfr less than 30 * any pre-existing illness with fever, weakness, or respiratory difficulties, pregnancy or breastfeeding. * doctors' judgements to inappropriate for inclusion

Keywords: l-type fatty acid-binding protein, beta 2 microglobulin
tomotherapy for refractory brain metastases

Conditions: Brain Metastases

Summary: this clinical trial was designed to investigate the efficiency and toxicity of tomotherapy for refractory brain metastases.

this is a single-arm, single center, phase ii trial to investigate the feasibility and toxicity of tomotherapy for refractory brain metastases, which are defined as a: multiple brain metastases(≥3 lesions); b: large brain metastases(with one lesion's volume is no smaller than 6cc or the longest diameter is no shorter than 3cm); c: meningeal metastases.

Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of primary tumor and conformed brain metastases by enhanced mri or ct; the lesion number is no less than 3; or the tumor volume is no smaller than 6cc; or tumor diameter is no shorter than 3cm; or uncontrolled brain tumor after whole brain radiotherapy(wbrt); or the tumor is adjacent to essential structures of the brain, such as brain stem, optic chiasma, optic tract, etc; kps ≥60,or kps ≥40 and the limitation of motion is simply caused by brain tumor that is adjacent to the motor function areas; age: 18-75 years old; adequate end-organ function: wbc≥4.0x109/l neu ≥ 1.5x109/l hemoglobin ≥ 110 g/l platelets ≥100 x109/l total bilirubin ≤ 1.5x uln ast and alt ≤ 1.5x uln bun and cr: within the normal range. exclusion criteria: * • other clinically significant diseases (e.g.myocardial infarction within the past 6 months, severe arrhythmia). * unable or unwilling to comply with the study protocol. * the expected survival time is less than 3 months. * patients who are anticipated in other clinical trials of brain metastases. * patients who has been treated with srt in other hospitals * pregnant patients or female patients whose hcg is positive * unsuitable to participate in study, that in the opinion of the treating physician.

Keywords: multiple brain metastases large brain metastases meningeal metastases tomotherapy
cardiovascular systems inc. (csi) pvad first in human study

Conditions: Coronary Artery Disease

Summary: this study will collect initial clinical data on the csi pvad system to inform device design and finalization.


Eligibility criteria:
inclusion criteria: 1. male or non- pregnant female ≥ 18 years of age 2. life expectancy ≥ 1 year 3. ejection fraction (ef) \>15% and ≤ 40% 4. scheduled for an elective high risk percutaneous coronary intervention exclusion criteria: 1. hemodynamically unstable mi with elevated cardiac biomarker and no evidence of at least 1 consecutive ck-mb or troponin value trending downward from a previous value or st-elevation myocardial infarction (stemi) within 14 days of index procedure 2. pre-procedure cardiac arrest within 24 hours of enrollment requiring cardiopulmonary resuscitation 3. cardiogenic shock 4. left ventricular (lv) mural thrombus 5. presence of a prosthetic valve or a heart constrictive device 6. aortic stenosis 7. moderate or severe aortic regurgitation (≥ 2+ by echo) 8. severe peripheral vascular disease that will preclude the use of a 12f access sheath, which is required for the insertion of the csi pvad catheter 9. severe aortic tortuosity 10. severe aortic calcification 11. vasculature will not tolerate a right heart catheterization 12. renal dysfunction (serum creatinine ≥ 2.5 mg/dl) or requirement for hemodialysis 13. liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3x upper lab normal (uln) or internationalized normalized ratio (inr) ≥ 2 or lactate dehydrogenase (ldh) \> 2.5x uln 14. uncorrectable abnormal coagulation parameters 15. history of heparin induced thrombocytopenia 16. sustained ventricular tachycardia 17. stroke or transient ischemic attack (tia) within 6 months or any permanent neurological deficit 18. chronic anemia (hemoglobin \< 8 g/dl) 19. subject may require long term support with a commercially available hemodynamic support device 20. active systemic infection requiring oral or intravenous antibiotics 21. allergy or intolerance to ionic and nonionic contrast media, anticoagulants, or antiplatelet therapy drugs that cannot be adequately premedicated 22. allergy or intolerance to system components 23. participation in another investigational drug or device study

Keywords: pvad high risk pci cardiovascular systems, inc. mechanical circulatory support (mcs)
validation of an online knee pain map and questionnaire: a probabilistic diagnostic tool

Conditions: Knee Pain

Summary: "blank" has designed a medical diagnostic system in the form of an unvalidated online questionnaire and drawing tool used to describe and identify the location of knee pain, respectively. a component of the survey includes the patient inputting their diagnosis as the etiology of their knee pain. dr. ivo dinov's team has used the data from 100,000 patient surveys to construct a probabilistic model to diagnose those who fill out the questionnaire and knee pain map but do not have a diagnosis. however, the validity of the online survey and the accuracy of the probabilistic model has not been confirmed in patients with known diagnoses. therefore, the purpose of this study will be to recruit patients with knee pain at ucla orthopedic clinics to complete the online survey which will then be applied to the probabilistic model to output possible diagnoses. the results will be compared to the actual diagnosis assigned to that patient in the clinic. if validated, the online survey may serve as a tool for diagnostic and research purposes.


Eligibility criteria:
inclusion criteria: * patients with knee pain and a known diagnosis for their pain * patients older than 18 years old exclusion criteria: * patients that are unable or unwilling to complete the online survey. * patients who do not have a diagnosis for their knee pain

Keywords: knee pain map questionnaire survey
the impact of family financial support on child health

Conditions: Child Overall Health Related Quality of Life

Summary: the investigators have partnered with financial coaching organizations to establish what the investigators have termed a "medical-financial partnership (mfp)" that offers financial coaching to improve financial and mental health.the investigators will evaluate the mfp's impact on child overall health rating.

financial coaching is a new tool in the field of community development, but it has already demonstrated significant financial impact in a number of studies, including one randomized trial conducted by the urban institute. financial coaching improves participant financial literacy, budgeting, saving for financial emergencies, and debt level. the investigators' project will help clinicians and the field of community economic development understand health and well-being through a new economic lens and assess the health-related impacts of the emerging field of financial coaching. the investigators have partnered with financial coaching organizations to establish what they have termed a "medical-financial partnership (mfp)" that offers financial coaching to improve financial and mental health. the investigators will evaluate the mfp's impact on parent-rated child overall health on a 5 point likert scale (excellent to poor). community-based participants will be recruited from south los angeles and randomized to receive either monthly financial coaching plus access to referral for social services (intervention) or access to referral for social services alone (control). inclusion criteria include having dependents under age 18, having some form of income, and having a tax identification number (social security number or individual tax identification number). participants will be surveyed quarterly regarding their parent-rated child overall health on a 5 point likert scale (excellent to poor).

Eligibility criteria:
inclusion criteria: * participants will include caregivers and parents with one or more dependent children, some form of income, and a tax identification number. exclusion criteria: * inability to take part in financial coaching or primary language other than english or spanish.

Keywords: child quality of life financial coaching socioeconomic status social determinants of health
a trial to evaluate the safety of once weekly dosing of somapacitan (nnc0195-0092) and daily norditropin® flexpro® for 52 weeks in previously human growth hormone treated japanese adults with growth hormone deficiency

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this trial is conducted in asia. the aim of this trial is to evaluate the safety of once weekly dosing of somapacitan (nnc0195-0092) and daily norditropin® flexpro® for 52 weeks in previously human growth hormone treated japanese adults with growth hormone deficiency.


Eligibility criteria:
inclusion criteria: - male or female of at least 18 years of age and not more than 79 years of age at the time of signing informed consent - ghd diagnosed for at least 6 months (defined as 180 days) prior to screening - treatment with hgh for at least 6 consecutive months (defined as 180 days) at screening - if applicable, hormone replacement therapies for any other hormone deficiencies, adequate and stable for at least 90 days prior to randomisation as judged by the investigator exclusion criteria: - active malignant disease or history of malignancy. exceptions to this exclusion criterion:1/ resected in situ carcinoma of the cervix and squamous cell or basal cell carcinoma of the skin with complete local excision 2/ subjects with ghd attributed to treatment of intracranial malignant tumours or leukaemia, provided that a recurrence-free survival period of at least 5 years is documented in the subject's medical records - for subjects with surgical removal or debulking of pituitary adenoma or other benign intracranial tumour within the last 5 years:evidence of growth of pituitary adenoma or other benign intracranial tumour within the last 12 months (defined as below or equal to 365 days) before randomisation. absence of growth must be documented by two post-surgery magnetic resonance imaging (mri) scans or ct scans. the most recent mri or ct scan must be performed below or equal to 9 months (defined as below or equal to 270 days) prior to randomisation
a. reducing radioiodine treatment in papillary thyroid cancer. railess

Conditions: to Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm

Summary: to study if its is safe to reduce the amount of postoperative treatments in those patients, who have been operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm, and in whom postoperative thyroglobulin levels are of low level.

the purpose of the study : to enroll about 50 patients operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm, and in whom postoperative thyroglobulin levels are of low level. methods: either to follow-up patients according to the study protocol without radioiodine treatment or to give a radioiodine treatment with a dose of 1.1 gbq according to the normal finnish treatment protocol for papillary thyroid cancer to those patients who themselves preferred to have a normal postoperative treatment.

Eligibility criteria:
inclusion criteria: * low risk papillary intrathyroidal thyroid cancer with diameter of 11-20mm * no lymphnode metastases exclusion criteria: * high risk papillary cancer * mutlifocal papillary cancer

Keywords: radioiodine treatment, low risk thyroid cancer, papillary thyroid cancer
determine the bioequivalence of two formulations of tamsulosin hcl capsules in fed male.

Conditions: Prostatic Hyperplasia

Summary: two tamsulosin hclformulations will be tested in fed state


Eligibility criteria:
inclusion criteria: health male volunteers 18 years and older exclusion criteria: history of hypersensitivity or allergy to imp or its excipients or any related medication
comparison of the incidence of shoulder pain according to postoperative use of abdominal binder

Conditions: Shoulder Pain

Summary: the aim of the study is to evaluate the effect of the use of an abdominal binder on postoperative shoulder pain according to laparoscopic gynecological surgery. the investigators will compare the incidences of shoulder pain after laparoscopic gynecological surgery in terms of the use of an abdominal binder.

laparoscopic surgery has advantages over laparotomy in that it reduces postoperative pain and hospital stay. however, postoperative shoulder pain is one of the major concerns of laparoscopic surgery. shoulder pain has been reported to occur in 35 to 70% of laparoscopic surgeries. the exact mechanism of shoulder pain after laparoscopic surgery is not clear. the main hypothesis is that the presence of residual carbon dioxide (co2) in the abdominal cavity stimulates the diaphragmatic nerve and causes pain in the shoulder. alveolar recruitment maneuver in the trendelenburg position reduced the intensity and incidence of shoulder pain significantly. however, even with these measures, shoulder pain occurred in 63% of patients after surgery. in addition to this measure, the investigators hypothesized that wearing an abdominal binder would promote the absorption of residual co2 in the abdominal cavity into the peritoneum and pelvis pressure. the aim of this study was to evaluate the effect of the use of an abdominal binder on shoulder pain after gynecological laparoscopic surgery. the intraoperative management is carried out in the same manner, except for wearing an abdominal binder after surgery. laparoscopic procedure is completed, and then intraperitoneal co2 is passive drained. an anesthetist places the operating table in the trendelenburg position at 30 degrees and performs the alveolar recruitment maneuver. (cpap 45 cm h2o is administered 5 times for 7 seconds) in the abdominal binder group, the patient wears an abdominal binder in the trendelenburg position and then changed to the supine position before the emergence. in the control group, the patient placed in the supine position, and emergence is started. shoulder pain at 12, 24, and 36 hours after surgery is investigated with a numeric score scale (nrs) score.

Eligibility criteria:
inclusion criteria: * adult patients aged 20-79 years with asa i - iii undergoing elective laparoscopic gynecological surgery under general anesthesia exclusion criteria: * patients who do not consent to the trial * conversion to open surgery from laparoscopic surgery * patients with previous shoulder disease or history of shoulder surgery * patients who have difficulty wearing an abdominal binder due to skin disease or wounds in the abdomen * development of subcutaneous emphysema * change of intra-abdominal carbon dioxide pressure due to surgical difficulties

Keywords: laparoscopic surgery gynecology
impact of a nutrition quality improvement program on outcomes of malnourished patients

Conditions: Malnutrition

Summary: a nutrition-focused qip will be implemented as standard of care at select branches of the home health division of the health care system. the qip will be comprised of three groups of patients, group 1 will consist of hospitalized, at-risk/malnourished patients being discharged to home health, group 2 will consist of outpatients at-risk/malnourished patients enrolled in home health and group 3 will consist of snf, at-risk/malnourished patients being discharged to home health. groups will be followed for 90 days post enrollment. the qip groups will be compared to historical controls, concurrent controls, and matched concurrent controls across other sites within the health system.


Eligibility criteria:
inclusion criteria: * admitted to home health from within the healthcare system's hospitals, skilled nursing facility (snf) or outpatient clinics * patient is screened positive for malnutrition during hospital stay and/or by home health nutrition screening tool upon enrollment into home health * patient is able to consume foods and beverages orally and the physician has not indicated otherwise exclusion criteria: * enrollment to home health from a hospital, snf or outpatient clinic not affiliated with the healthcare system * patient is pregnant * patient is intubated, receiving tube feeding or parenteral nutrition * patient has severe dementia or delirium * history of significant psychiatric disorder * any other disorder that may interfere with qip product consumption or compliance with qip protocol procedures as per the admitting clinicians * subject has stated an allergy or intolerance to any of the ons ingredients * patients receiving hospice care